Sinopharm and Provectus Extend MOU Negotiations for Six Months

Sinopharm (China National Pharmaceutical Group) and Provectus Biopharma of the US have extended their MOU for another six months to May 16, 2015. During the first three months of the agreement (see story), the two companies were not able to come to terms on China rights for Provectus's lead drug candidate: PV-10, a cancer immunotherapy. According to reports, Sinopharm will study the recently published protocol for the melanoma Phase III trial of PV-10 to "understand the drug better." More details.... Stock Symbol: (NYSE: PVCT) Share this with colleagues: // //